The research-based pharmaceutical industry says the decision to waive intellectual property protections for COVID-19 vaccines is fundamentally flawed and will have a negative impact on future innovation.
Research-based industry says IP waiver an 'empty shell' and fact-free decision
June 19, 2022 Latest NewsBioPharma
Latest Video
New Stories
-
PYC reports strong clinical momentum and cash position ahead of key readouts
October 27, 2025 - - Australian Biotech -
Government backs new national push to close bone health testing gap for women
October 27, 2025 - - Latest News -
Leadership change at PolyNovo as long-time Chair steps down
October 27, 2025 - - Australian Biotech -
Cann Group announces major debt restructure and capital raise to strengthen balance sheet
October 27, 2025 - - Australian Biotech -
FDA awards the first-ever national priority vouchers to nine sponsors
October 27, 2025 - - Latest News -
Cancer Australia looks to accelerate the delivery of national plan
October 27, 2025 - - Latest News -
Mark Butler announces the addition of another contraceptive option to the PBS
October 27, 2025 - - Latest News
